January 25, 2021

Niv Krikov Chief Financial Officer Agrify Corporation 101 Middlesex Turnpike Suite 6, PMB 326 Burlington, MA 01803

Re: Agrify Corp

Amendment No. 1 to

Registration

Statement on Form S-1

2021

Filed January 13,

File No. 333-251616

Dear Mr. Krikov:

 $\label{eq:weak-decomposition} \mbox{We have reviewed your amended registration statement and have the following}$

comments. In some of our comments, we may ask you to provide us with information so we

may better understand your disclosure.

 $\,\,$ Please respond to this letter by amending your registration statement and providing the

requested information. If you do not believe our comments apply to your facts and $% \left(1\right) =\left(1\right) +\left(1\right) +$

circumstances or do not believe an amendment is appropriate, please tell us why in your $% \left(1\right) =\left(1\right) \left(1\right)$

response.

 $\qquad \qquad \text{After reviewing any amendment to your registration statement and the information you} \\$

provide in response to these comments, we may have additional comments. Unless we note

otherwise, our references to prior comments are to comments in our January 4, 2021 letter.

Amendment No. 1 to Registration Statement on Form S-1

Summary Financial and Other Data, page 14

1. We note your response to prior comment 13 from our letter dated September 8, 2020 that you intended to include pro forma earnings per share disclosures. We see here and on page 41 that you present "Net income (loss) per share, basic and diluted" that is not otherwise included or discussed in the filing. Please revise to include historical and pro forma earnings per share information including calculations supporting the weighted average shares

outstanding used for both.

Niv Krikov

Agrify Corporation

January 25, 2021

Page 2

Capitalization, page 38

2. We see that you have revised to include derivative liabilities within the Indebtedness line $\$

item. Please revise the line item label to identify its inclusion. Overview, page $60\,$

3. On page 61, you revised the discussion of your recent purchase orders. Previously, you

stated that three of your four last purchase orders were between \$7.2 and \$11.1 million.

Now, you state four of your last five purchase orders were between \$2.3 and \$11.1

million. You continue to state in the next sentence that you "expect that [y]our average

contract size will increase over time as well as we begin to partner with larger facilities that require more equipment and services." This revision appears to counter the trend you are citing. Provide your analysis supporting this trend. Our Customers, page 79 On page 80, you updated sales or potential sales figures. Previously, you stated you had 1,909 AVFUs "deployed and/or booked," and a \$121 million pipeline. Now you have 1,526 AVFUs "deployed or booked" and a \$105 million backlog. Provide your analysis for the decrease in both numbers. For example, tell us whether both decreased because you determined that bookings would not come to fruition. Revise to quantify what portion of the 1,526 AVFUs are deployed and what portion are booked. Executive Compensation, page 91 We note you revised the disclosure regarding the employment agreements. Previously you filed the agreements with Mr. Krikov, Mr. Harrison and Mr. Stamm as exhibits. It appears those exhibits have been deleted. Please include these exhibits. Financial Statements Note 9. Capital FirstName Structure, Krikov LastNameNiv page F-16 Comapany NameAgrify Please Corporation revise all disclosures to reflect the reverse stock split, for example it does not Januaryappear thatPage your2June 2019 issuance of 2,040,000 shares reflects the 25, 2021 split. FirstName LastName Niv Krikov FirstName LastNameNiv Krikov Agrify Corporation Comapany January 25, NameAgrify 2021 Corporation January Page 3 25, 2021 Page 3 FirstName LastName You may contact Julie Sherman at (202) 551-6902 or Kevin Kuhar at (202) you have questions regarding comments on the financial statements and related matters. Please contact Abby Adams at (202) 551-6902 or Mary Beth Breslin at (202) 551-3625 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences

David Levine, Esq.